Your browser is no longer supported. Please, upgrade your browser.
Settings
RTRX Retrophin, Inc. daily Stock Chart
RTRX [NASD]
Retrophin, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own0.90% Shs Outstand43.81M Perf Week-1.92%
Market Cap982.66M Forward P/E- EPS next Y-2.64 Insider Trans-17.13% Shs Float31.74M Perf Month5.31%
Income-102.70M PEG- EPS next Q-0.59 Inst Own- Short Float12.43% Perf Quarter-0.75%
Sales164.20M P/S5.98 EPS this Y-67.60% Inst Trans-0.01% Short Ratio11.58 Perf Half Y-23.24%
Book/sh7.71 P/B2.91 EPS next Y-9.50% ROA-17.00% Target Price47.71 Perf Year-7.16%
Cash/sh10.76 P/C2.08 EPS next 5Y20.00% ROE-33.50% 52W Range19.77 - 33.00 Perf YTD-0.88%
Dividend- P/FCF- EPS past 5Y-0.80% ROI-18.30% 52W High-32.03% Beta1.01
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin96.60% 52W Low13.45% ATR0.87
Employees214 Current Ratio4.70 Sales Q/Q3.80% Oper. Margin-59.10% RSI (14)51.17 Volatility3.93% 3.97%
OptionableYes Debt/Eq0.68 EPS Q/Q56.30% Profit Margin-62.50% Rel Volume0.94 Prev Close23.73
ShortableYes LT Debt/Eq0.61 EarningsFeb 26 AMC Payout- Avg Volume340.64K Price22.43
Recom1.40 SMA200.79% SMA502.34% SMA200-12.10% Volume321,233 Change-5.48%
Nov-19-18Initiated Nomura Buy $57
Aug-17-18Initiated Canaccord Genuity Buy $36
Nov-02-15Initiated JMP Securities Mkt Outperform $30
Jun-04-15Reiterated Deutsche Bank Buy $52 → $55
May-15-15Initiated Avondale Mkt Outperform
Apr-28-15Initiated Deutsche Bank Buy $50
Mar-24-19 08:13AM  Edited Transcript of RTRX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-14-19 11:20AM  Retrophin (RTRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
Mar-07-19 12:53PM  Will Retrophin, Inc.s (NASDAQ:RTRX) Earnings Grow In The Next Couple Of Years? Simply Wall St.
Mar-06-19 08:15AM  Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-05-19 04:30PM  Retrophin to Present at Upcoming Investor Conferences GlobeNewswire
Feb-28-19 08:00AM  Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers GlobeNewswire
Feb-26-19 10:01PM  Retrophin Inc (RTRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
02:30PM  Retrophin, Inc. to Host Earnings Call ACCESSWIRE
Feb-14-19 04:30PM  Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-12-19 04:30PM  Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-08-19 08:03AM  Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View Zacks
Feb-04-19 07:35AM  Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-17-19 06:55AM  Citron Says Ligand Has 80% Downside in Explosive Note Investopedia
Jan-07-19 07:00AM  Retrophin Provides Corporate Update and 2019 Outlook GlobeNewswire
Jan-04-19 07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga
Jan-03-19 04:30PM  Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer GlobeNewswire
Jan-02-19 04:30PM  Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-27-18 08:00AM  Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy GlobeNewswire
Dec-20-18 08:00AM  Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN GlobeNewswire
Dec-14-18 03:13AM  Retrophin Inc (RTRX) Hedge Funds Are Snapping Up Insider Monkey
Dec-05-18 09:32AM  How Does Retrophin Inc (NASDAQ:RTRX) Affect Your Portfolio Volatility? Simply Wall St.
Nov-28-18 04:30PM  Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference GlobeNewswire +5.58%
08:50AM  Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-12-18 07:00AM  Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria GlobeNewswire
Nov-08-18 01:17PM  Edited Transcript of RTRX earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
12:36PM  Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript Motley Fool
Nov-07-18 04:30PM  Retrophin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-01-18 06:50PM  Retrophin (RTRX) Reports Q3 Loss, Lags Revenue Estimates Zacks +7.95%
05:46PM  Retrophin: 3Q Earnings Snapshot Associated Press
04:01PM  Retrophin Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-29-18 08:44PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders Business Wire
Oct-26-18 09:18PM  Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis GlobeNewswire
Oct-25-18 04:01PM  Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology GlobeNewswire
Oct-19-18 09:10AM  New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-18-18 04:30PM  Retrophin to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-05-18 04:01PM  Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018 GlobeNewswire
Oct-03-18 04:30PM  Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses GlobeNewswire
Sep-27-18 04:30PM  Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy GlobeNewswire
Sep-17-18 04:30PM  Retrophin to Present at Upcoming Investor Conferences GlobeNewswire
Sep-05-18 08:32PM  Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering GlobeNewswire -10.61%
08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
Sep-04-18 04:07PM  Retrophin Announces Proposed Convertible Senior Notes Offering GlobeNewswire
Aug-21-18 08:15AM  New Research Coverage Highlights pdvWireless, Fortuna Silver Mines, Nordic American Tankers, Amarin, Himax Technologies, and Retrophin Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-17-18 07:37PM  Martin Shkrelis Former Lawyer Sentenced to 18 Months in Prison The Wall Street Journal +5.36%
06:03PM  Ex-lawyer of pharma executive Shkreli gets 18 months prison for fraud scheme Reuters
05:56PM  Martin Shkreli's Former Lawyer Sentenced to 18 Months in Prison The Wall Street Journal
05:52PM  Ex-lawyer of pharma exec Shkreli gets 18 months prison for fraud scheme Reuters
05:16PM  Martin Shkreli's Company Lawyer Sentenced to 18 Months for Fraud Bloomberg
Aug-01-18 09:09AM  Edited Transcript of RTRX earnings conference call or presentation 26-Jul-18 8:30pm GMT Thomson Reuters StreetEvents
Jul-30-18 04:30PM  Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer GlobeNewswire
Jul-26-18 04:05PM  Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan GlobeNewswire
08:16AM  Retrophin Earnings Preview Benzinga
Jul-12-18 04:30PM  Retrophin to Report Second Quarter 2018 Financial Results GlobeNewswire
Jun-14-18 08:00AM  Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued U.S. Patent GlobeNewswire
Jun-06-18 07:50AM  Research Report Identifies Corbus Pharmaceuticals, Retrophin, Charter Financial, HighPoint Resources, Southern First Bancshares, and Oaktree Specialty Lending with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jun-04-18 08:00AM  Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients GlobeNewswire
May-24-18 04:30PM  Retrophin to Present at Upcoming Investor Conferences GlobeNewswire
May-23-18 04:30PM  Retrophin Receives Workplace Excellence Award GlobeNewswire
May-07-18 05:14AM  Edited Transcript of RTRX earnings conference call or presentation 1-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-01-18 05:13PM  Retrophin: 1Q Earnings Snapshot Associated Press
04:01PM  Retrophin Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-23-18 05:56PM  Fight brews over Shkreli's Wu-Tang album as 'pharma bro' gets banned by securities industry CNBC
Apr-19-18 01:07PM  Shkreli arrives at low-security prison in New Jersey American City Business Journals
Apr-17-18 04:30PM  Retrophin to Report First Quarter 2018 Financial Results GlobeNewswire
Apr-12-18 08:10AM  New Research Coverage Highlights Woori Bank, Texas Capital Bancshares, Retrophin, SPS Commerce, Corbus Pharmaceuticals, and EnPro Industries Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +6.29%
Apr-10-18 11:55AM  'Pharma bro' fraudster Martin Shkreli ordered to pay $388,000 in restitution to swindled investor CNBC
Apr-03-18 08:00AM  Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis GlobeNewswire
Mar-27-18 02:06PM  Pharma bro Martin Shkreli appeals fraud conviction as judge mulls restitution award CNBC -5.63%
Mar-16-18 06:36PM  Shkreli bragged exam would would show 150 IQ and 'no overt psychological issues.' He was wrong CNBC
07:35AM  Analysis: Positioning to Benefit within Capella Education, Access National, Randgold Resources, Diodes, Silicon Motion Technology, and Retrophin Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-14-18 01:56PM  'Pharma bro' fraudster Martin Shkreli: I want to serve prison in a minimum-security federal camp CNBC
01:05PM  Shkreli asks judge to recommend a high-security federal prison in Pennsylvania American City Business Journals
Mar-09-18 04:12PM  'Pharma Bro' Shkreli sentenced to 7 years for defrauding investors Reuters
03:48PM  'Pharma Bro' Shkreli sentenced to 7 years for defrauding investors Reuters
02:19PM  'Pharma Bro' Shkreli sentenced to seven years for defrauding investors Reuters
02:16PM  'Pharma Bro' Shkreli sentenced to 7 years for defrauding investors Reuters
02:10PM  'Pharma Bro' Martin Shkreli Gets 7 Years In Prison For Securities Fraud Benzinga
01:57PM  Martin Shkreli Sentenced to Seven Years in Prison Bloomberg
01:56PM  'Pharma bro' Martin Shkreli sentenced to 7 years in prison says 'This is my fault' CNBC
Mar-08-18 10:00AM  Martin Shkrelis Journey From Pharma Exec to Inmate #87850-053 Bloomberg
Mar-06-18 12:59PM  Prosecutors ask judge to put 'pharma bro' Martin Shkreli in prison for at least 15 years CNBC
Mar-05-18 04:30PM  Retrophin Announces Appointment of Casey Logan as Vice President of Corporate Development GlobeNewswire
12:49PM  Martin Shkreli must forfeit $7.36 million, turn over stake in ultra-rare Wu-Tang Clan album: Judge CNBC
Feb-28-18 04:30PM  Retrophin to Present at the Barclays Global Healthcare Conference GlobeNewswire +5.21%
03:39PM  'Pharma bro' Martin Shkreli tells judge: 'I was a fool' CNBC
01:57PM  'Kind, caring, generous' Martin Shkreli wants sentence of just 12 to 18 months in prison CNBC
01:08PM  'Pharma bro' Shkreli seeks 12 to 18 month sentence, below guidelines Reuters
Feb-27-18 06:15PM  Retrophin reports 4Q loss Associated Press
04:01PM  Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
12:50PM  Retrophin, Inc. to Host Earnings Call ACCESSWIRE
12:43PM  Retrophin Q4 Earnings Preview Benzinga
Feb-26-18 01:13PM  'Pharma bro' Shkreli to be held responsible for $10.4 million in losses: U.S. judge Reuters
01:07PM  Big 'loss' for Martin Shkreli: Judge's ruling means 'pharma bro' could get decade or more in prison CNBC
Feb-23-18 01:28PM  Martin Shkreli sports a jailhouse beard as judge weighs big questions on investors' losses CNBC +6.76%
01:22PM  Shkreli loses bid to toss stock manipulation conviction Reuters
Feb-13-18 04:30PM  Retrophin to Report Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-01-18 04:30PM  Retrophin to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-15-18 08:35AM  Are Options Traders Betting on a Big Move in Retrophin (RTRX) Stock? Zacks
Jan-08-18 07:00AM  Retrophin Provides Corporate Update and 2018 Outlook GlobeNewswire
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTE WILLIAM E.Senior Vice President, R&DFeb 19Sale21.521,25026,90013,810Feb 20 07:58 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 15Sale21.441,25026,80015,060Feb 20 07:58 PM
ASELAGE STEVEChief Executive OfficerFeb 12Sale21.501,06522,898257,642Feb 13 08:47 PM
Clague LauraChief Financial OfficerFeb 12Sale21.501,01621,84410,000Feb 13 08:49 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryFeb 12Sale21.5088419,00614,558Feb 13 08:50 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 12Sale21.5099221,32816,007Feb 13 08:49 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 11Sale21.3899321,23016,999Feb 13 08:49 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryFeb 11Sale21.3888518,92115,442Feb 13 08:50 PM
Clague LauraChief Financial OfficerFeb 11Sale21.381,01721,74311,016Feb 13 08:49 PM
ASELAGE STEVEChief Executive OfficerFeb 11Sale21.381,06522,770258,707Feb 13 08:47 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 09Sale23.8275017,86516,327Jan 09 07:43 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 08Sale24.0975018,06817,077Jan 09 07:43 PM
Clague LauraChief Financial OfficerDec 21Sale21.833,75081,86012,033Dec 21 08:19 PM
ASELAGE STEVEChief Executive OfficerDec 21Sale21.796,188134,829259,772Dec 21 08:20 PM
ASELAGE STEVEChief Executive OfficerDec 20Sale21.976,188135,958265,960Dec 21 08:20 PM
McFarlane Neil F.Chief Operating OfficerDec 20Sale22.3211,125248,33328,956Dec 21 08:21 PM
Clague LauraChief Financial OfficerDec 20Sale22.083,75082,80515,783Dec 21 08:19 PM
ASELAGE STEVEChief Executive OfficerDec 07Sale24.0410240251,523Dec 07 09:15 PM
ASELAGE STEVEChief Executive OfficerNov 15Sale24.325,550134,969253,283Nov 16 07:16 PM
ROTE WILLIAM E.Senior Vice President, R&DNov 15Sale24.322,50060,80017,992Nov 16 07:17 PM
Clague LauraChief Financial OfficerNov 15Sale24.313,75091,16712,033Nov 16 07:16 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryNov 15Sale24.332,50060,81617,827Nov 16 07:18 PM
McFarlane Neil F.Chief Operating OfficerNov 14Sale23.7310,000237,31428,476Nov 16 07:19 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryNov 14Sale23.732,50059,33020,327Nov 16 07:18 PM
Clague LauraChief Financial OfficerNov 14Sale23.733,75088,97015,783Nov 16 07:16 PM
ROTE WILLIAM E.Senior Vice President, R&DNov 14Sale23.732,50059,32920,492Nov 16 07:17 PM
ASELAGE STEVEChief Executive OfficerNov 14Sale23.745,550131,735258,833Nov 16 07:16 PM
ASELAGE STEVEChief Executive OfficerAug 31Option Exercise8.7012,000104,400257,883Aug 31 07:54 PM
ASELAGE STEVEChief Executive OfficerAug 31Sale32.0012,000384,000245,883Aug 31 07:54 PM